Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox and Bosch to Launch Game-Changing POC Coronavirus Test

By LabMedica International staff writers
Posted on 28 Mar 2020
Global diagnostics company Randox Laboratories (Crumlin, UK) and leading technology manufacturer Bosch Healthcare Solutions GmbH (Waiblingen, Germany) will launch a game-changing point of care coronavirus test in April 2020. More...
The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses. This provides a more comprehensive respiratory screening which enables precise and informed treatment decisions to be made.

Randox’s diagnostic products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories. With a major focus in R&D, Randox scientists work in pioneering research into a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease. The company’s patented Biochip Array Technology is the world’s only diagnostic grade biochip, offering a unique testing platform which allows multiple tests to be carried out from a single patient sample. Bosch Healthcare Solutions develops products and services that draw on the Bosch Group’s core competencies, such as sensors to collect data, software to evaluate that data, and services based on this data analysis.

The Viral Respiratory Tract Infection Array is one of the world’s first multiplex molecular diagnostic tests meeting the COVID-19 testing recommendations of the World Health Organization (WHO) and the Centers for Disease Control (CDC). The target gene for COVID-19 being used on the VRI array is ORF1ab, and for Sarbecovirus (SARS, SARS like, SARS-CoV-2) is E gene, representing conserved regions of the genome which have been chosen for their high sensitivity and specificity.

The new VRI test will be conducted on Vivalytic, a point of care platform brought to the market by Randox and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed which minimizes the risk of contamination, require room temperature storage (space-saving), contain all the reagents on-board the cartridge and utilizes end point PCR. The test only requires a single nasal swab from the patient and an easy four step process to be carried out by the user to run the patient sample.

With the Vivalytic VRI test, physicians can quickly and efficiently distinguish between different infections with very similar symptoms, like influenza, and immediately begin the appropriate treatment. The test delivers a reliable result based on WHO guidelines in less than 2.5 hours at the point of care, i.e. in close proximity to where the patient’s sample was collected. This means a time-consuming logistics chain, in which the samples have to be transported, is no longer necessary.

“This array focuses not only on the identification of the novel coronavirus strain that causes COVID-19, but also nine other respiratory infection targets simultaneously, including Influenza A and B, Sarbecovirus and MERS,” said Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences. “The aim is to diagnose patients fast and accurately from a single genetic sample, maximizing containment of the virus whilst minimizing the spread. With the development of this array onto a fully automated platform, patients can be diagnosed rapidly at point of care locations globally such as pharmacies and doctor surgeries.”

Related Links:
Randox Laboratories
Bosch Healthcare Solutions GmbH



Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.